Sarah M. Zimmerman

Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity

Lisa K. Brents, Emily E. Reichard, Sarah M. Zimmerman et al. · PLoS ONE · 2011 · 214 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

In vivo Effects of Abused ‘Bath Salt’ Constituent 3,4-methylenedioxypyrovalerone (MDPV) in Mice: Drug Discrimination, Thermoregulation, and Locomotor Activity

William E. Fantegrossi, Brenda M. Gannon, Sarah M. Zimmerman et al. · Neuropsychopharmacology · 2012 · 148 citations · Full text

Medicine, Neurobiology, Pharmacology +6

Interaction of 5-HT2A and 5-HT2C Receptors in R(−)-2,5-Dimethoxy-4-iodoamphetamine-Elicited Head Twitch Behavior in Mice

William E. Fantegrossi, Jean-Aim� Simoneau, M. S. Cohen et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 124 citations · Full text

Medicine, Neuroscience, Pharmacology +17

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies

Kathryn A. Seely, Lisa K. Brents, Lirit N. Franks et al. · Neuropharmacology · 2012 · 101 citations

Medicine, Pharmacology, Molecular Pharmacology +15

Differential Drug–Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy

Lisa K. Brents, Sarah M. Zimmerman, Amanda Saffell et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 56 citations · Full text

Medicine, Pharmacology, Behavioral Pharmacology +10